1~2 item / All 2 items
Displayed results
Added to bookmarks
Bookmarks listBookmark has been removed
Bookmarks listYou can't add any more bookmarks
By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.
Free membership registrationContact this company
Contact Us OnlineBefore making an inquiry
Download PDF1~2 item / All 2 items
At Renac Therapeutics, we handle "Pharmaceutical Pipeline NASH Therapeutics (Nucleic Acid Medicines)." Using our proprietary technology, Hetero Double-Stranded Nucleic Acid (HDO) technology, we have discovered compounds that inhibit the expression of the NASH-related gene IHH. These compounds are expected to improve the NAFLD activity score in NASH animal models by inhibiting IHH expression, paving the way for the development of a novel NASH therapeutic. [Features] - Effectively inhibits the expression of the NASH-related gene IHH. - Also suppresses the expression of fibrosis marker genes such as COL1A1, CTGF, and TIMP1, suggesting potential as a fibrosis treatment. *For more details, please refer to the PDF document or feel free to contact us.
Added to bookmarks
Bookmarks listBookmark has been removed
Bookmarks listYou can't add any more bookmarks
By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.
Free membership registrationOur company handles "Hetero Double-Stranded Nucleic Acid (HDO)," which can selectively deliver active strands to disease sites by binding ligands to carrier strands, thereby expecting high therapeutic efficacy. HDO has a double-stranded structure, making it inherently stable. It avoids chemical modifications to the active strand, which can reduce toxicity. 【Features】 ■ Selectively delivers active strands to disease sites, achieving high therapeutic efficacy ■ Avoids chemical modifications and reduces toxicity ■ Provides a structurally stable material, improving enzyme resistance in the bloodstream ■ Low likelihood of unexpected therapeutic effects ■ Allows for free selection of the position and number of ligands binding to the carrier strand ■ The HDO technology is licensed to Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals (USA), Nippon Shokubai Co., Ltd., and Nippon Gene Material Co., Ltd. ■ The HDO technology is covered by multiple registered patents, ensuring safe use. ■ Collaborative research using HDO technology for drug discovery can also be conducted with our company. *For more details, please download the PDF or contact us.
Added to bookmarks
Bookmarks listBookmark has been removed
Bookmarks listYou can't add any more bookmarks
By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.
Free membership registration